PE20060297A1 - Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1 - Google Patents
Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1Info
- Publication number
- PE20060297A1 PE20060297A1 PE2005000666A PE2005000666A PE20060297A1 PE 20060297 A1 PE20060297 A1 PE 20060297A1 PE 2005000666 A PE2005000666 A PE 2005000666A PE 2005000666 A PE2005000666 A PE 2005000666A PE 20060297 A1 PE20060297 A1 PE 20060297A1
- Authority
- PE
- Peru
- Prior art keywords
- sglt
- inhibitors
- alkylene
- fluoroglycosidic
- pyrazoles
- Prior art date
Links
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 title abstract 2
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 102100029795 Sodium-dependent glucose transporter 1 Human genes 0.000 abstract 1
- 101710181093 Sodium-dependent glucose transporter 1 Proteins 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON CADA UNO F, H; A ES UN ENLACE, O, NH, CH2, S; R3 ES H, HALOGENO, OH, CN, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, CICLOALQUILO C3-C6, ENTRE OTROS; B ES ALQUILENO C0-C15 SIENDO REEMPLAZADO O NO UNO O MAS CARBONOS DEL ALQUILENO POR O-, -(C=O)-, -CH=CH-, ENTRE OTROS; R5, R6 Y R7 SON CADA UNO H, HALOGENO, OH, COOH, ALQUILO C1-C6, ENTRE OTROS; R8 Y R9 SON CADA UNO H, SO3H, ALQUILO C1-C6, OH, ENTRE OTROS; X ES CO, O, NH, ENTRE OTROS; L ES ALQUILENO C1-C6, ALQUENILENO C2-C5 PUDIENDO ESTAR REEMPLAZADO 1-2 GRUPOS CH2 POR O o NH; Y ES UN ENLACE, CO, NHCO, SO, SO2. SON COMPUESTOS PREFERIDOS: A, B, ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE GLUCOSA DEPENDIENTE DE SODIO 1 (SGLT 1), UTILES EN EL TRATAMIENTO DE DIABETES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004028241A DE102004028241B4 (de) | 2004-06-11 | 2004-06-11 | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060297A1 true PE20060297A1 (es) | 2006-05-25 |
Family
ID=35355753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000666A PE20060297A1 (es) | 2004-06-11 | 2005-06-10 | Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7820804B2 (es) |
| EP (1) | EP1758914B1 (es) |
| JP (1) | JP4996464B2 (es) |
| CN (1) | CN100582116C (es) |
| AR (1) | AR049393A1 (es) |
| AU (1) | AU2005252329B2 (es) |
| BR (1) | BRPI0510770A (es) |
| CA (1) | CA2570042C (es) |
| CR (1) | CR8773A (es) |
| CY (1) | CY1107426T1 (es) |
| DE (2) | DE102004028241B4 (es) |
| DK (1) | DK1758914T3 (es) |
| EC (1) | ECSP067054A (es) |
| ES (1) | ES2296180T3 (es) |
| HR (1) | HRP20080023T3 (es) |
| IL (1) | IL179757A (es) |
| MA (1) | MA28653B1 (es) |
| MX (1) | MXPA06013513A (es) |
| MY (1) | MY143565A (es) |
| NO (1) | NO20070176L (es) |
| NZ (1) | NZ551948A (es) |
| PE (1) | PE20060297A1 (es) |
| PL (1) | PL1758914T3 (es) |
| PT (1) | PT1758914E (es) |
| RS (1) | RS50541B (es) |
| RU (1) | RU2370499C2 (es) |
| SI (1) | SI1758914T1 (es) |
| TN (1) | TNSN06409A1 (es) |
| TW (1) | TWI382030B (es) |
| UA (1) | UA89787C2 (es) |
| UY (1) | UY28955A1 (es) |
| WO (1) | WO2005121161A1 (es) |
| ZA (1) | ZA200608832B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7973012B2 (en) | 2006-05-19 | 2011-07-05 | Taisho Pharmaceutical Co., Ltd | C-phenyl glycitol compound |
| AU2007266078B2 (en) * | 2006-06-29 | 2011-12-15 | Taisho Pharmaceutical Co., Ltd. | C-phenyl 1-thioglucitol compound |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US20100069460A1 (en) | 2006-12-14 | 2010-03-18 | Taisho Pharmaceutical Co., Ltd. | 1-phenyl 1-thio-d-glucitol derivative |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5272395B2 (ja) * | 2007-12-12 | 2013-08-28 | セントラル硝子株式会社 | ４−デオキシ−４−フルオロ−ｄ−グルコース誘導体の製造方法 |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| ES2380408T3 (es) * | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MY155658A (en) | 2009-02-23 | 2015-11-13 | Taisho Pharmaceutical Co Ltd | A-isopropylphenyl glucitol compounds as sglti inhibitors |
| MX2012001729A (es) * | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| EP2298782A1 (en) * | 2009-08-26 | 2011-03-23 | Sanofi-Aventis | Method for producing pyrazole glycoside derivatives |
| US20120270819A1 (en) | 2009-10-02 | 2012-10-25 | Sanofi | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone disease |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| WO2011051864A1 (en) | 2009-11-02 | 2011-05-05 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| BR112012011726A2 (pt) | 2009-11-13 | 2020-05-19 | Bristol-Myers Squibb Company | comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas |
| JP5798123B2 (ja) | 2009-11-13 | 2015-10-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低質量のメトホルミン製剤 |
| JP5784623B2 (ja) | 2009-11-13 | 2015-09-24 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 速放性錠剤製剤 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| AU2011291709B2 (en) | 2010-08-20 | 2014-03-27 | Taisho Pharmaceutical Co., Ltd. | Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof |
| JP5532138B2 (ja) | 2010-08-20 | 2014-06-25 | 大正製薬株式会社 | ４−イソプロピル−６−メトキシフェニルグルシトール化合物 |
| WO2012031124A2 (en) | 2010-09-03 | 2012-03-08 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
| MX2013008372A (es) | 2011-02-01 | 2013-08-12 | Astrazeneca Uk Ltd | Formulaciones farmaceuticas que incluyen compuesto de amina. |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8614195B2 (en) * | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| UA113086C2 (xx) * | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
| TW201425326A (zh) | 2012-10-05 | 2014-07-01 | Lilly Co Eli | 新穎脲化合物 |
| ES2694110T3 (es) | 2013-02-04 | 2018-12-18 | Taisho Pharmaceutical Co., Ltd. | Fármaco profiláctico o terapéutico para el estreñimiento |
| EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
| AR098670A1 (es) | 2013-11-08 | 2016-06-08 | Lilly Co Eli | Inhibidor de sglt1 |
| EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
| KR102806676B1 (ko) * | 2018-04-04 | 2025-05-13 | 니뽄 다바코 산교 가부시키가이샤 | 헤테로아릴로 치환된 피라졸 화합물 및 그의 의약 용도 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW406086B (en) * | 1996-12-26 | 2000-09-21 | Tanabe Seiyaku Co | Propiophenone derivatives and process for preparing the same |
| KR100591585B1 (ko) * | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체 |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| AU2002210990A1 (en) * | 2000-11-02 | 2002-05-15 | Ajinomoto Co. Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
| WO2002064839A2 (en) * | 2001-02-14 | 2002-08-22 | Tularik Inc. | Methods for the diagnosis and treatment of tumors employing the hepsin gene |
| EP1432720A1 (en) * | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| WO2004014932A1 (ja) * | 2002-08-08 | 2004-02-19 | Kissei Pharmaceutical Co., Ltd. | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP4606876B2 (ja) * | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
| CA2500873C (en) * | 2002-10-04 | 2012-01-17 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| KR20050089156A (ko) * | 2002-12-04 | 2005-09-07 | 깃세이 야쿠힌 고교 가부시키가이샤 | 고혈당증에 기인하는 질환의 예방 또는 치료제 |
| DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| ES2377741T3 (es) * | 2003-06-20 | 2012-03-30 | Kissei Pharmaceutical Co., Ltd. | Derivados de pirazol, composición farmacológica que los contiene e intermedios de producción de los mismos |
-
2004
- 2004-06-11 DE DE102004028241A patent/DE102004028241B4/de not_active Expired - Fee Related
-
2005
- 2005-06-03 SI SI200530142T patent/SI1758914T1/sl unknown
- 2005-06-03 RS RSP-2008/0017A patent/RS50541B/sr unknown
- 2005-06-03 CA CA2570042A patent/CA2570042C/en not_active Expired - Fee Related
- 2005-06-03 PL PL05746637T patent/PL1758914T3/pl unknown
- 2005-06-03 NZ NZ551948A patent/NZ551948A/en not_active IP Right Cessation
- 2005-06-03 JP JP2007526254A patent/JP4996464B2/ja not_active Expired - Fee Related
- 2005-06-03 PT PT05746637T patent/PT1758914E/pt unknown
- 2005-06-03 EP EP05746637A patent/EP1758914B1/de not_active Expired - Lifetime
- 2005-06-03 ES ES05746637T patent/ES2296180T3/es not_active Expired - Lifetime
- 2005-06-03 AU AU2005252329A patent/AU2005252329B2/en not_active Ceased
- 2005-06-03 HR HR20080023T patent/HRP20080023T3/xx unknown
- 2005-06-03 WO PCT/EP2005/005959 patent/WO2005121161A1/de not_active Ceased
- 2005-06-03 MX MXPA06013513A patent/MXPA06013513A/es active IP Right Grant
- 2005-06-03 UA UAA200700259A patent/UA89787C2/ru unknown
- 2005-06-03 CN CN200580019067A patent/CN100582116C/zh not_active Expired - Fee Related
- 2005-06-03 RU RU2007101154/04A patent/RU2370499C2/ru not_active IP Right Cessation
- 2005-06-03 BR BRPI0510770-9A patent/BRPI0510770A/pt not_active IP Right Cessation
- 2005-06-03 DK DK05746637T patent/DK1758914T3/da active
- 2005-06-03 DE DE502005002056T patent/DE502005002056D1/de not_active Expired - Lifetime
- 2005-06-09 TW TW094118973A patent/TWI382030B/zh not_active IP Right Cessation
- 2005-06-09 MY MYPI20052616A patent/MY143565A/en unknown
- 2005-06-10 UY UY28955A patent/UY28955A1/es unknown
- 2005-06-10 PE PE2005000666A patent/PE20060297A1/es not_active Application Discontinuation
- 2005-06-13 AR ARP050102406A patent/AR049393A1/es not_active Application Discontinuation
-
2006
- 2006-10-24 ZA ZA200608832A patent/ZA200608832B/en unknown
- 2006-11-27 CR CR8773A patent/CR8773A/es not_active Application Discontinuation
- 2006-11-30 IL IL179757A patent/IL179757A/en not_active IP Right Cessation
- 2006-12-05 MA MA29515A patent/MA28653B1/fr unknown
- 2006-12-06 US US11/567,410 patent/US7820804B2/en not_active Expired - Fee Related
- 2006-12-08 TN TNP2006000409A patent/TNSN06409A1/en unknown
- 2006-12-08 EC EC2006007054A patent/ECSP067054A/es unknown
-
2007
- 2007-01-10 NO NO20070176A patent/NO20070176L/no not_active Application Discontinuation
-
2008
- 2008-02-04 CY CY20081100139T patent/CY1107426T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060297A1 (es) | Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1 | |
| PE20040771A1 (es) | Derivados de fluoroglicosidos heterociclicos como inhibidores del transportador de glucosa dependiente de sodio | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| PE20061353A1 (es) | Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa | |
| PE20080361A1 (es) | Compuestos derivados de purina como activadores del receptor de adenosina a2a | |
| NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
| PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| PE20071095A1 (es) | Derivados policiclicos de indazol como inhibidores de erk | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20140608A1 (es) | Analogos de nucleotidos sustituidos | |
| PE20090422A1 (es) | Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1 | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
| PE20030976A1 (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20090772A1 (es) | Derivados de bencimidazol | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| PE20061377A1 (es) | Compuestos heterociclicos fusionados | |
| PE20060949A1 (es) | Derivados fusionados de pirazol como agonistas del receptor de niacina | |
| PE20061096A1 (es) | Derivados de oxiindol como agonistas 5-ht4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |